Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_MetaanalyseFabien Zoulim et al.AASLD 2019Download the poster herePoster Presentation

Published 8 November 2019
Categorized as -others, 2019, Publication, TG1050

Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming

Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation

Published 6 November 2019
Categorized as -others, 2019, Invir.IO, Publication

Transgene Will Participate in the Jefferies 2019 London Healthcare Conference

20191022 – Transgene PR Jefferies EN

Published 22 October 2019
Categorized as 2019, Press release

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation

Published 30 September 2019
Categorized as -others, 2018, 2019, Publication, TG4001, TG4001, TG6002 (FR)

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

Published 30 September 2019
Categorized as 2019, Press release, TG4001, TG4001

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 30 September 2019
Categorized as -others, 2023, Publication, TG4001, TG4001

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation

Published 27 September 2019
Categorized as -others, 2019, 2025, Publication, publication key en, TG4001, TG4001, TG4050

Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

20190918-Transgene-H1-2019-RESULTS-EN

Published 18 September 2019
Categorized as 2019, Press release

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050

20190916 PR ANSM TG4050 EN

Published 16 September 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

20190829 PR financial Agenda

Published 29 August 2019
Categorized as 2019, Press release

Posts pagination

Newer posts Page 1 … Page 28 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu